Article
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Acta neuropathologica communications - 4 Nov 2020
Fontanilles Maxime, Marguet Florent, Beaussire Ludivine, Magne Nicolas, Pépin Louis-Ferdinand, Alexandru Cristina, Tennevet Isabelle, Hanzen Chantal, Langlois Olivier, Jardin Fabrice, Laquerrière Annie, Sarafan-Vasseur Nasrin, Di Fiore Fréderic, Clatot Florian
Abstract excerpt
The clinical implications of plasmatic cell-free and tumor DNA (cfDNA and ctDNA) are challenging in glioblastoma. This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma (n = 3) patients treated with concomitant temozolomide and radiotherapy (RT-TMZ), followed by a TMZ maintenance phase. Plasma samples were collected at baseline, before RT-TMZ (pre-RT-TMZ) and at the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.